Growth Metrics

Dna X (SONM) Gross Profit (2018 - 2025)

Dna X filings provide 8 years of Gross Profit readings, the most recent being $1.8 million for Q3 2025.

  • On a quarterly basis, Gross Profit fell 57.09% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.8 million, a 28.83% decrease, with the full-year FY2024 number at $9.9 million, down 48.66% from a year prior.
  • Gross Profit hit $1.8 million in Q3 2025 for Dna X, up from $845000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $8.4 million in Q1 2025 to a low of -$487000.0 in Q4 2021.
  • Median Gross Profit over the past 5 years was $2.9 million (2024), compared with a mean of $3.1 million.
  • Biggest five-year swings in Gross Profit: plummeted 113.06% in 2021 and later surged 907.39% in 2022.
  • Dna X's Gross Profit stood at -$487000.0 in 2021, then surged by 907.39% to $3.9 million in 2022, then surged by 30.21% to $5.1 million in 2023, then plummeted by 103.57% to -$183000.0 in 2024, then surged by 1092.35% to $1.8 million in 2025.
  • The last three reported values for Gross Profit were $1.8 million (Q3 2025), $845000.0 (Q2 2025), and $8.4 million (Q1 2025) per Business Quant data.